Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Activating EGFR Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableNot Yet RecruitingNCT07287904
What this trial is testing

Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data

Who this might be right for
Lung Cancer (NSCLC)EGFR Activating MutationAdenocarcinoma Lung+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 1,000
Testing effectiveness (Phase 2)Study completedNCT03732352
What this trial is testing

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

Who this might be right for
EGFR Gene AmplificationEGFR Gene MutationGlioblastoma+3 more
Jonsson Comprehensive Cancer Center 12
Testing effectiveness (Phase 2)Study completedNCT01153984
What this trial is testing

Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations

Who this might be right for
Carcinoma，Non-Small-Cell Lung
Hoffmann-La Roche 23
Testing effectiveness (Phase 2)Ended earlyNCT02630186
What this trial is testing

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 3
Large-scale testing (Phase 3)Study completedNCT01774721
What this trial is testing

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Who this might be right for
Non-small Cell Lung Cancer With EGFR-Activating Mutations
Pfizer 452
Not applicableLooking for participantsNCT07348965
What this trial is testing

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)Leptomeningeal MetastasisFurmonertinib+1 more
Guangzhou University of Traditional Chinese Medicine 42
Testing effectiveness (Phase 2)Study completedNCT02108964
What this trial is testing

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Who this might be right for
Advanced Non-small Cell Lung Cancer
Novartis Pharmaceuticals 225
Not applicableTemporarily Not AvailableNCT01297101
What this trial is testing

Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy

Who this might be right for
Non-small Cell Lung Cancer
Shanghai Chest Hospital
Testing effectiveness (Phase 2)Study completedNCT05258279
What this trial is testing

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Who this might be right for
Non-squamous Non-small-cell Lung CancerEGFR Activating Mutation
Juntendo University 30
Testing effectiveness (Phase 2)Study completedNCT02629523
What this trial is testing

Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA

Who this might be right for
Lung NeoplasmsEGFR Gene Mutation
Chonnam National University Hospital 21
Not applicableStudy completedNCT01723878
What this trial is testing

ASPET Study: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced Non-Small Cell Lung Cancer Harbouring EGFR Activating Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 144
Testing effectiveness (Phase 2)WithdrawnNCT02355431
What this trial is testing

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Who this might be right for
Solid Tumors and Hematologic MalignancyNSCLC (Non-small Cell Lung Carcinoma)
Incyte Corporation
Testing effectiveness (Phase 2)WithdrawnNCT03240393
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
CarcinomaNon-Small-Cell Lung Cancer
Novartis Pharmaceuticals
Not applicableActive Not RecruitingNCT05103605
What this trial is testing

Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 274
Large-scale testing (Phase 3)Study completedNCT00949650
What this trial is testing

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Who this might be right for
Carcinoma, Non-Small-Cell LungAdenocarcinoma
Boehringer Ingelheim 345
Testing effectiveness (Phase 2)Looking for participantsNCT06760819
What this trial is testing

Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Who this might be right for
Advanced Solid TumorsHER2 Mutation
Bayer 111
Large-scale testing (Phase 3)UnknownNCT02883543
What this trial is testing

First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 330
Testing effectiveness (Phase 2)Study completedNCT02414139
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 373
Not applicableUnknownNCT05136014
What this trial is testing

Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model

Who this might be right for
Lung CancerLung AdenocarcinomaEGFR Activating Mutation+2 more
Central Hospital, Nancy, France 200
Large-scale testing (Phase 3)Ended earlyNCT02178397
What this trial is testing

Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR

Who this might be right for
NSCLC Patients With EGFR Activating Mutation
Centre Francois Baclesse 6
Next Page